Tracking Baker Brothers Portfolio – Q3 2020 Update

• Baker Brothers’ 13F portfolio value increased from $22.67B to $25.03B this quarter. 
• The large stake in BeiGene was increased during the quarter. 
• The top three positions are Seattle Genetics, BeiGene, and Incyte Corporation and they add up to almost ~64% of the portfolio. 

 This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 11/16/2020.

 

This quarter, Baker Brothers’ 13F portfolio value increased ~10% from ~$22.67B to ~$25.03B. The top three holdings are at ~64% while the top five holdings are at ~75% of the 13F assets: Seattle Genetics (SGEN), BeiGene (BGNE), Incyte Corporation (INCY), Acadia Pharma (ACAD), and Alexion Pharmaceuticals (ALXN).

 

The spreadsheet below highlights changes to Baker Brothers’ 13F holdings in Q3 2020. For a look at how the portfolio has progressed, please see our previous update:

 

 

 

To learn more about how to profit from a strategy of following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little Guy .